MAZE Stock — Maze Therapeutics Inc.: Cash, EV, Pipeline

Share price

$22.52

Market cap

$1,251.0M

Cash

$411.1M

Enterprise value

$878.9M

Balance sheet

Cash	$411.1M
Debt	$39.0M
Net cash	$372.1M
Enterprise value	$878.9M
Basic shares	55.5M shares
Fully diluted shares	67.9M shares
Fully diluted market cap	$1,528.9M
Cash per share	$7.41

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MAZE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	MZE829	Phase 2	Proteinuric Kidney Disease	—
Jan 12 - Feb 23	MZE782	Phase 2	Phenylketonuria (PKU)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MZE829

Phase 2 · Active Modality: oral small molecule

Target APOL1 (apolipoprotein L1)

Indications

APOL1-mediated kidney disease (AMKD) (Phase 2)

Catalysts

— late 2026 or early 2027 / H1 2027

Status note Lead program. Phase 2 initiated Nov 2024 (ongoing open-label trial in adults with APOL1 high-risk genotype proteinuric CKD); topline proof-of-concept data announced Mar 2026; enrollment continuing.

MZE782

Phase 2 · Active Modality: oral small molecule

Target SLC6A19

Indications

Phenylketonuria (PKU) (Phase 2)
Chronic kidney disease (CKD) (Stage not disclosed)

Catalysts

— 2027
— H1 2027

Status note Phase 1 in healthy volunteers completed Sep 2025. Phase 2 proof-of-concept trial in PKU initiated Aug 2026; Phase 2 proof-of-concept trial in CKD planned for H1 2027.

MZE001

Phase 2 · Active Modality: oral small molecule

Aliases S606001

Target GYS1 (glycogen synthase 1)

Partnerships Shionogi & Co., Ltd.: exclusive worldwide license (Mar 2024); $150M upfront, up to $275M in clinical/regulatory milestones, up to $330M in sales milestones, tiered royalties; $20M clinical milestone achieved Mar 2026

Indications

Pompe disease (Phase 2)

Status note Partnered program fully licensed to Shionogi. Shionogi-led Phase 2 ongoing; first patient dosed Mar 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	MZE782
Lead indication	Phenylketonuria (PKU)
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07694440	Phase 2	Recruiting	Sponsor	Maze Therapeutics	—	Phenylketonuria (PKU)	—
NCT06830629	Phase 2	Recruiting	Sponsor	Maze Therapeutics	—	Proteinuric Kidney Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Maze Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	5,032,915	+465,641	3.27%	2026-08-14
Logos Global Management	1,935,000	+700,000	2.49%	2026-08-14
Braidwell LP	1,140,040	+1,140,040	1.26%	2026-08-14
Sphera Biotech	417,564	+190,221	1.78%	2026-08-14
Ikarian Capital	378,999	no change	1.85%	2026-08-14
ADAR1 Capital Management	339,276	+289,181	0.48%	2026-08-14
RTW Investments	212,000	+212,000	0.05%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MAZE — Maze Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders